Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Darapladib on Blister Inflammation in T2DM
NCT02058641Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of darapladib in atherosclerosis (2 arms), sponsored by GSK. Primary endpoint: Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid up to 6 weeks. Started Feb 2014; status: completed.
02
Drugs
darapladib
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02058641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058641.